Tiziana Life Sciences (TLSA) Competitors $0.97 -0.03 (-2.86%) (As of 10:30 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends TLSA vs. CGC, AKBA, KALV, VERV, TKNO, LRMR, FDMT, VALN, DNA, and CTNMShould you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Canopy Growth (CGC), Akebia Therapeutics (AKBA), KalVista Pharmaceuticals (KALV), Verve Therapeutics (VERV), Alpha Teknova (TKNO), Larimar Therapeutics (LRMR), 4D Molecular Therapeutics (FDMT), Valneva (VALN), Ginkgo Bioworks (DNA), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry. Tiziana Life Sciences vs. Canopy Growth Akebia Therapeutics KalVista Pharmaceuticals Verve Therapeutics Alpha Teknova Larimar Therapeutics 4D Molecular Therapeutics Valneva Ginkgo Bioworks Contineum Therapeutics Tiziana Life Sciences (NASDAQ:TLSA) and Canopy Growth (NASDAQ:CGC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, community ranking, dividends and analyst recommendations. Does the MarketBeat Community favor TLSA or CGC? Tiziana Life Sciences received 76 more outperform votes than Canopy Growth when rated by MarketBeat users. Likewise, 63.58% of users gave Tiziana Life Sciences an outperform vote while only 19.42% of users gave Canopy Growth an outperform vote. CompanyUnderperformOutperformTiziana Life SciencesOutperform Votes9663.58% Underperform Votes5536.42% Canopy GrowthOutperform Votes2019.42%Underperform Votes8380.58% Which has preferable earnings and valuation, TLSA or CGC? Tiziana Life Sciences has higher earnings, but lower revenue than Canopy Growth. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTiziana Life SciencesN/AN/A-$17.69MN/AN/ACanopy Growth$220.27M1.85-$487.23M-$4.93-0.78 Is TLSA or CGC more profitable? Tiziana Life Sciences has a net margin of 0.00% compared to Canopy Growth's net margin of -186.17%. Tiziana Life Sciences' return on equity of 0.00% beat Canopy Growth's return on equity.Company Net Margins Return on Equity Return on Assets Tiziana Life SciencesN/A N/A N/A Canopy Growth -186.17%-74.29%-29.94% Do institutionals and insiders believe in TLSA or CGC? 3.3% of Canopy Growth shares are held by institutional investors. 39.8% of Tiziana Life Sciences shares are held by insiders. Comparatively, 1.3% of Canopy Growth shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor TLSA or CGC? In the previous week, Canopy Growth had 4 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 5 mentions for Canopy Growth and 1 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.00 beat Canopy Growth's score of 0.38 indicating that Tiziana Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tiziana Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Canopy Growth 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, TLSA or CGC? Tiziana Life Sciences has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500. Comparatively, Canopy Growth has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Do analysts prefer TLSA or CGC? Canopy Growth has a consensus target price of $3.50, indicating a potential downside of 9.33%. Given Canopy Growth's stronger consensus rating and higher probable upside, analysts clearly believe Canopy Growth is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Canopy Growth 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 SummaryTiziana Life Sciences beats Canopy Growth on 8 of the 14 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSA vs. The Competition Export to ExcelMetricTiziana Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$102.39M$6.48B$5.07B$8.80BDividend YieldN/A8.11%4.99%4.07%P/E RatioN/A4.9789.5613.60Price / SalesN/A371.451,224.8087.40Price / CashN/A52.5939.4536.27Price / Book19.4310.306.976.33Net Income-$17.69M$153.61M$119.04M$225.93M7 Day Performance5.10%-1.73%-1.78%-0.96%1 Month Performance12.31%-7.26%-3.59%1.06%1 Year Performance67.51%31.10%31.64%26.59% Tiziana Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSATiziana Life Sciences0.5462 of 5 stars$0.97-2.9%N/A+75.4%$102.39MN/A0.008Positive NewsCGCCanopy Growth1.4699 of 5 stars$3.86+2.7%$3.50-9.3%-36.3%$406.69M$220.27M0.001,029AKBAAkebia Therapeutics3.9344 of 5 stars$1.77-1.1%$5.75+224.9%+75.5%$386.18M$194.62M-7.78167KALVKalVista Pharmaceuticals3.7142 of 5 stars$8.90-0.7%$26.00+192.1%+9.1%$384.66MN/A0.00150Insider TradeNews CoverageVERVVerve Therapeutics2.4428 of 5 stars$4.50-1.1%$25.75+472.2%-63.2%$380.97M$11.76M0.00110TKNOAlpha Teknova0.7174 of 5 stars$7.10-8.3%$5.00-29.6%+279.4%$378.50M$36.68M0.00240LRMRLarimar Therapeutics3.678 of 5 stars$5.86-3.6%$20.43+248.6%+93.6%$373.93MN/A0.0030Analyst ForecastFDMT4D Molecular Therapeutics3.0058 of 5 stars$8.03-4.5%$42.13+424.6%-32.1%$371.23M$20.72M-2.76201Analyst ForecastAnalyst RevisionVALNValneva2.2966 of 5 stars$4.47-4.3%$18.50+313.9%-62.1%$363.19M$165.52M0.00700Gap DownDNAGinkgo Bioworks1.1366 of 5 stars$6.44+1.3%$4.58-29.0%N/A$357.94M$251.46M0.001,218Short Interest ↓CTNMContineum Therapeutics1.6433 of 5 stars$13.70+0.4%$29.25+113.5%N/A$353.19M$50M0.0031 Related Companies and Tools Related Companies CGC Competitors AKBA Competitors KALV Competitors VERV Competitors TKNO Competitors LRMR Competitors FDMT Competitors VALN Competitors DNA Competitors CTNM Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TLSA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
